ADC Therapeutics Releases Preliminary Revenue Estimates for 2025 and Clinical Updates
ADC Therapeutics, a leader in the development of antibody-drug conjugates, recently provided preliminary insights into its financial performance and upcoming clinical activities for 2025. According to the unaudited data, the company anticipates achieving approximately $22 million in net product revenue for the fourth quarter and a total of around $73 million for the entire year. This revenue reflects a slight increase from previous year figures, demonstrating steady demand for their flagship product, ZYNLONTA.
As of December 31, 2025, the company reported cash and cash equivalents totaling about $261 million, which positions them well for operational stability, projecting a cash runway that extends at least until 2028. This financial confidence is essential as they prepare for several critical catalysts in the coming months.
Among these catalysts, ADC Therapeutics is set to complete enrollment for the LOTIS-7 trial in the first half of 2026. This study aims to evaluate the effectiveness of ZYNLONTA in combination with the bispecific antibody glofitamab for patients suffering from relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). Early results from LOTIS-7 have been promising, showing an impressive 89.8% overall response rate and a 77.6% complete response rate from 49 patients who had at least six months of follow-up.
Another key highlight is the anticipated topline data from the LOTIS-5 Phase 3 trial in 2Q 2026, which focuses on ZYNLONTA in conjunction with rituximab for patients with 2L+ DLBCL. The company plans to release full results by the end of 2026. Assuming successful outcomes, ADC Therapeutics envisions submitting a supplemental Biologics License Application (sBLA) to the U.S. FDA and potentially achieving regulatory approvals in mid-2027.
In addition to these ongoing trials, ADC Therapeutics has initiated several investigator-initiated trials (IITs) of ZYNLONTA aimed at treating indolent lymphomas. Initial results from these trials have displayed promising efficacy and manageable safety profiles. The findings are expected to be published by late 2026, further contributing to the body of evidence supporting ZYNLONTA's use.
The company successfully completed IND-enabling activities for a new prostate-targeting ADC based on exatecan, which could provide further diversification of their product portfolio.
ADC Therapeutics has firmly established itself in the biotechnology sector and remains committed to innovating treatment options. The firm's progress during 2025 showcases their sustained efforts in clinical development and corporate expansion. The anticipated results from various trials and strategies for regulatory approval will likely pave the way for accelerated revenue growth starting in 2027.
With these updates, ADC Therapeutics not only reinforces its market position but also aims to potentially reshape therapeutic landscapes that benefit patients across various malignancies. As they move forward, all eyes will be on the upcoming trial results and the opportunities that lie ahead for both the company and its stakeholders.
As of December 31, 2025, the company reported cash and cash equivalents totaling about $261 million, which positions them well for operational stability, projecting a cash runway that extends at least until 2028. This financial confidence is essential as they prepare for several critical catalysts in the coming months.
Among these catalysts, ADC Therapeutics is set to complete enrollment for the LOTIS-7 trial in the first half of 2026. This study aims to evaluate the effectiveness of ZYNLONTA in combination with the bispecific antibody glofitamab for patients suffering from relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). Early results from LOTIS-7 have been promising, showing an impressive 89.8% overall response rate and a 77.6% complete response rate from 49 patients who had at least six months of follow-up.
Another key highlight is the anticipated topline data from the LOTIS-5 Phase 3 trial in 2Q 2026, which focuses on ZYNLONTA in conjunction with rituximab for patients with 2L+ DLBCL. The company plans to release full results by the end of 2026. Assuming successful outcomes, ADC Therapeutics envisions submitting a supplemental Biologics License Application (sBLA) to the U.S. FDA and potentially achieving regulatory approvals in mid-2027.
In addition to these ongoing trials, ADC Therapeutics has initiated several investigator-initiated trials (IITs) of ZYNLONTA aimed at treating indolent lymphomas. Initial results from these trials have displayed promising efficacy and manageable safety profiles. The findings are expected to be published by late 2026, further contributing to the body of evidence supporting ZYNLONTA's use.
The company successfully completed IND-enabling activities for a new prostate-targeting ADC based on exatecan, which could provide further diversification of their product portfolio.
ADC Therapeutics has firmly established itself in the biotechnology sector and remains committed to innovating treatment options. The firm's progress during 2025 showcases their sustained efforts in clinical development and corporate expansion. The anticipated results from various trials and strategies for regulatory approval will likely pave the way for accelerated revenue growth starting in 2027.
With these updates, ADC Therapeutics not only reinforces its market position but also aims to potentially reshape therapeutic landscapes that benefit patients across various malignancies. As they move forward, all eyes will be on the upcoming trial results and the opportunities that lie ahead for both the company and its stakeholders.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.